Small molecule · Inhibitor of Myeloid cell leukemia 1 (MCL1) (MCL1) · developed by Prelude Therapeutics
PRT1419 is an inhibitor of the anti-apoptotic protein MCL1, a Bcl-2 family member upregulated in cancer cells. It binds MCL1 and prevents it from inactivating pro-apoptotic proteins, promoting apoptosis of cells overexpressing MCL1. It is studied in hematologic malignancies including acute myeloid leukemia and several B-cell lymphomas and leukemias.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05107856 | Phase 1 | Acute Myeloid Leukemia | Terminated | PRLD |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Myeloid LeukemiaB-cell Non-Hodgkin LymphomaChronic Lymphocytic LeukemiaChronic Myelomonocytic LeukemiaFollicular LymphomaMantle Cell LymphomaMarginal Zone LymphomaMyelodysplastic SyndromesMyeloproliferative NeoplasmSmall Lymphocytic Lymphoma
Updated Oct 25, 2026. Something wrong or missing? Report it on the PRLD page.
See PRLD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PRLD catalysts and pipeline →